NAS:ARCT ()
Arcturus Therapeutics Holdings Inc $ 47.05 -0.22 (-0.47%)
Volume:
333,275
Avg Vol (1m):
912,348
Market Cap $:
1.15 Bil
Enterprise Value $:
1.03 Bil
P/E (TTM):
0.00
P/B:
9.47
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.55 | ||
| Equity-to-Asset | 0.62 | ||
| Debt-to-Equity | 0.22 | ||
| Debt-to-EBITDA | -0.57 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 11.58 | ||
| Beneish M-Score | -3.44 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -337.1 | ||
| Net Margin % | -341.76 | ||
| ROE % | -99.28 | ||
| ROA % | -41.6 | ||
| ROC (Joel Greenblatt) % | -489.92 | ||
| 3-Year Revenue Growth Rate | -44.4 | ||
| 3-Year EBITDA Growth Rate | -63.2 | ||
| 3-Year EPS without NRI Growth Rate | -40.8 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 9.56 | ||
| PS Ratio | 55.75 | ||
| EV-to-EBIT | -27.77 | ||
| EV-to-EBITDA | -28.63 | ||
| EV-to-Revenue | 92.68 | ||
| Current Ratio | 6.16 | ||
| Quick Ratio | 6.16 | ||
| Days Sales Outstanding | 91.75 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -56.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 9.56 | ||
| Earnings Yield (Greenblatt) % | -3.61 |